Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?-Reference-Cited by-同舟云学术

Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?

Published:2013-03-21 Issue:3 Volume:15 Page:276-285
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Trammel Morgan,Roederer Mary,Patel Jai,McLeod Howard

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11912-013-0312-x.pdf

Reference54 articles.

1. Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684(1–3):1–7.

2. Blower PR. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J. 2002;8(5):405–14.

3. • Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011;22(1):30–8. This is a review focusing on the mechanism of CINV and the problems associated with treatment.

4. •• Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189–98. These guidelines are widely used in patient care for the treatment and prevention of CINV.

5. •• Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia Consensus Conference. Ann Oncol. 2010;21 Suppl 5:v232–43. These guidelines are widely used in patient care for the treatment and prevention of CINV.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients;Cancer Chemotherapy and Pharmacology;2024-04-27

2. Machine learning as a tool to identify inpatients who are not at risk of adverse drug events in a large dataset of a tertiary care hospital in the USA;British Journal of Clinical Pharmacology;2023-08

3. Metagenomics and chemotherapy‐induced nausea: A roadmap for future research;Cancer;2021-10-13

4. An Update in Our Understanding of the Relationships Between Gene Polymorphisms and Chemotherapy-Induced Nausea and Vomiting;International Journal of General Medicine;2021-09

5. Pharmacogenomics in cancer supportive care: key issues and future directions;Supportive Care in Cancer;2021-08-01